HER-2 - A possible target for therapy of metastatic urinary bladder carcinoma

Acta Oncologica

Volumn 41, Issue 3, 2002, Pages 282-288

  Wester, K ^b   Sjostrom A ^b   Torre, M D L ^b   Carlsson, J ^b   Malmstrom P U ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; FORMALDEHYDE; PARAFFINS; PATIENT TREATMENT; TISSUE;

URINARY BLADDER;

ONCOLOGY;

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARAFFIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS;

EID: 0036331813     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860260088836     Document Type: Article

References (47)

1. Current management of invasive and metastatic transitional cell carcinoma of the bladder
2. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
3. Basic science of HER-2/neu: A review
4. HER-2/neu (c-erb-B2) gene and protein in breast cancer
5. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer
6. Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance
7. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
8. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: A preliminary report
9. The expression of epidermal growth factor receptor on human bladder cancer: Potential use in radioimmunoscintigraphy
10. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma
11. The epidermal growth factor receptor and the prognosis of bladder cancer
12. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer
13. Cellular localisation of human epidermal growth factor receptor
14. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues
15. Expression of epidermal growth factor receptor in urinary bladder cancer metastases
16. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues
17. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
18. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: A study in Greek patients
19. A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues
20. Brief, high-temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues
21. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder
22. An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer
23. Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters
24. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer
25. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer
26. Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer
27. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis
28. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma
29. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer
30. Stability of HER-2/neu expression over time and at multiple metastatic sites
31. Biomarker conservation in primary and metastatic epithelial ovarian cancer
32. Increased level of c-erbB-2/neu/HER-2 protein in cutaneous squamous cell carcinoma
33. c-erbB-2 (HER-2/ neu) oncopeptide immunoreactivity in localized, high-grade transitional cell carcinoma of the bladder
34. C-erbB-2 gene amplification: A molecular marker in recurrent bladder tumors?
35. c-erbB-2 oncoprotein expression in primary human tumors
36. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
37. Comparison of immunohistological staining with antibodies to the c-erbB-2 oncoprotein
38. Increased HER2 with US food and drug administration-approved antibody
39. Heterogeneity of erbB-2 gene amplification in bladder cancer
40. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
41. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
42. Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis
43. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
44. C-erbB-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value
45. Expression of c-erbB-2 gene product in urinary bladder cancer
46. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer